<?xml version="1.0" encoding="UTF-8"?>
<p id="p0100">Umifenovir is name of arbidol, which is an original Russian antiviral drug widely used for etiotropic therapy of influenza and flu. In 2011, the WHO rendered an international nonproprietary name Umifenovir to an active ingredient of arbidol but the original name given to this drug by its creators is still much more common and familiar both to patients and researchers. Up to now, its primary therapeutic action has not yet been known for certain: whether it is a direct antiviral activity, stimulation of immune system or anti-inflammatory action [
 <xref rid="bib60" ref-type="bibr">60</xref>,
 <xref rid="bib61" ref-type="bibr">61</xref>]. Agent EIDD-2801 works similarly to remdesivir, acting as nucleoside analogs that metabolize into an active form that blocks RNA polymerase, an essential component of viral replication. It is being studied in five Phase III trials against COVID-19. This drug candidate can be taken in pill form [
 <xref rid="bib62" ref-type="bibr">62</xref>,
 <xref rid="bib63" ref-type="bibr">63</xref>]. Ribavirin (Rebetol®, Virazole®, etc.) is a synthetic nucleoside antiviral drug, which is approved by FDA for treatment of respiratory syncytial virus and hepatitis C virus infection. This drug, discovered in 1972, can be administered to humans by aerosol, oral and intravenous routes with a range of dosing regimens in different clinical settings. Ribavirin was found clinically effective against influenza, herpesvirus infections, hemorrhagic fever and Lassa fever but ineffective against Ebola and Marburg viruses [
 <xref rid="bib64" ref-type="bibr">[64]</xref>, 
 <xref rid="bib65" ref-type="bibr">[65]</xref>, 
 <xref rid="bib66" ref-type="bibr">[66]</xref>, 
 <xref rid="bib67" ref-type="bibr">[67]</xref>].
</p>
